All In Biotech

Drug Trial Radar · NCT06127043

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Dec 4, 2023

Primary completion

Jan 2026

Study completion May 2026

Sponsor

Lead sponsor
AnaptysBio, Inc.Industry
Sponsor type
Industry
First posted
Nov 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)

Conditions

  • Ulcerative Colitis

Interventions

  • RosnilimabDrug

    PD-1 agonist antibody

  • PlaceboDrug

    Administered via SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in modified Mayo Score (mMs) from Baseline to Week 12Time frame: Baseline to Week 12

Locations

100 sites in 15 countries. Site status is shown where the registry gives one.

  • AnaptysBio Investigational Site 10-115

    Phoenix, Arizona

  • AnaptysBio Investigational Site 10-117

    Garden Grove, California

  • AnaptysBio Investigational Site 10-112

    Lancaster, California

  • AnaptysBio Investigational Site 10-129

    Lancaster, California

  • AnaptysBio Investigational Site 10-108

    San Jose, California

  • AnaptysBio Investigational Site 10-127

    Brooksville, Florida

  • AnaptysBio Investigational Site 10-106

    Miami, Florida

  • AnaptysBio Investigational Site 10-109

    Miami Gardens, Florida

  • AnaptysBio Investigational Site 10-131

    Orlando, Florida

  • AnaptysBio Investigational Site 10-123

    Orlando, Florida

  • AnaptysBio Investigational Site 10-125

    Tampa, Florida

  • AnaptysBio Investigational Site 10-122

    Atlanta, Georgia

  • AnaptysBio Investigational Site 10-124

    Oak Lawn, Illinois

  • AnaptysBio Investigational Site 10-118

    Las Vegas, Nevada

  • AnaptysBio Investigational Site 10-133

    Utica, New York

  • AnaptysBio Investigational Site 10-136

    Cincinnati, Ohio

  • AnaptysBio Investigational Site 10-120

    Norman, Oklahoma

  • AnaptysBio Investigational Site 10-103

    Kingsport, Tennessee

  • AnaptysBio Investigational Site 10-104

    Dallas, Texas

  • AnaptysBio Investigational Site 10-113

    Garland, Texas

  • AnaptysBio Investigational Site 10-135

    Georgetown, Texas

  • AnaptysBio Investigational Site 10-134

    Lubbock, Texas

  • AnaptysBio Investigational Site 10-130

    Southlake, Texas

  • AnaptysBio Investigational Site 10-132

    Tyler, Texas

  • AnaptysBio Investigational Site 10-107

    Seattle, Washington

  • AnaptysBio Investigational Site 12-101

    Innsbruck, Austria

  • AnaptysBio Investigational Site 12-104

    Salzburg, Austria

  • AnaptysBio Investigational Site 12-103

    Sankt Pölten, Austria

  • AnaptysBio Investigational Site 12-102

    Vienna, Austria

  • AnaptysBio Investigational Site 61-102

    Sofia, Bulgaria

  • AnaptysBio Investigational Site 11-105

    Calgary, Canada

  • AnaptysBio Investigational Site 11-102

    London, Ontario, Canada

  • AnaptysBio Investigational Site 11-103

    Montreal, Quebec, Canada

  • AnaptysBio Investigational Site 74-104

    Rijeka, Croatia

  • AnaptysBio Investigational Site 74-101

    Zagreb, Croatia

  • AnaptysBio Investigational Site 16-102

    Nantes, France

  • AnaptysBio Investigational Site 16-103

    Nantes, France

  • AnaptysBio Investigational Site 16-101

    Tours, France

  • AnaptysBio Investigational Site 59-106

    Tbilisi, Georgia

  • AnaptysBio Investigational Site 59-103

    Tbilisi, Georgia

Showing 40 of 100 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.